Arrowhead Pharmaceuticals, Inc.
ARWR
Xếp hạng trong cổ phiếu
#2370
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Giá cổ phiếu
$59.06
Đồng bộ lần cuối: 2026-10-20
Vốn hóa thị trường
$8.34B
Thay đổi (1 ngày)
3.20%
Thay đổi (1 năm)
55.30%
Quốc gia
US
Giao dịch Arrowhead Pharmaceuticals, Inc. (ARWR)
Danh mục
Healthcare
Lịch sử chia tách cổ phiếu của Arrowhead Pharmaceuticals, Inc. (ARWR)
Cổ phiếu Arrowhead Pharmaceuticals, Inc. (mã: ARWR) đã trải qua tổng cộng 2 lần chia tách.
Lần chia tách gần nhất diễn ra vào ngày Nov 17, 2011.
Một cổ phiếu ARWR mua trước ngày Jan 15, 2004 hiện tương đương với 0.0015384615384615 cổ phiếu ARWR.
Lần chia tách gần nhất diễn ra vào ngày Nov 17, 2011.
Một cổ phiếu ARWR mua trước ngày Jan 15, 2004 hiện tương đương với 0.0015384615384615 cổ phiếu ARWR.
Danh sách chia tách cổ phiếu
| Năm | Chia tách | Tỷ lệ | Tỷ lệ cộng dồn |
|---|---|---|---|
| 2011-11-17 | 1:10 | x0.1 | x0.0015384615384615 |
| 2004-01-15 | 1:65 | x0.015384615384615 | x0.015384615384615 |
Chia tách cổ phiếu của các công ty tương tự hoặc đối thủ
| Công ty | Số lần chia tách cổ phiếu | Tỷ lệ cộng dồn | Quốc gia |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
